Antidepressants for COVID-19: A systematic review

Journal of Affective Disorders, Journal Year: 2022, Volume and Issue: 307, P. 108 - 114

Published: March 23, 2022

Language: Английский

---

Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19

Journal of Clinical Medicine, Journal Year: 2022, Volume and Issue: 11(19), P. 5882 - 5882

Published: Oct. 5, 2022

To reduce Coronavirus Disease 2019 (COVID-19)-related mortality and morbidity, widely available oral COVID-19 treatments are urgently needed. Certain antidepressants, such as fluvoxamine or fluoxetine, may be beneficial against COVID-19. We included 388,945 adult inpatients who tested positive for SARS-CoV-2 at 36 AP−HP (Assistance Publique−Hôpitaux de Paris) hospitals from 2 May 2020 to November 2021. compared the prevalence of antidepressant use admission in a 1:1 ratio matched analytic sample with without (N = 82,586), assessed its association 28-day all-cause 1482). Antidepressant was significantly less prevalent than control group (1.9% versus 4.8%; Odds Ratio (OR) 0.38; 95%CI 0.35−0.41, p < 0.001). associated reduced among (12.8% 21.2%; OR 0.55; 0.41−0.72, 0.001), particularly daily doses least 40 mg fluoxetine equivalents. Antidepressants high FIASMA (Functional Inhibitors Acid Sphingomyelinase) activity seem drive both associations. These infections COVID-19-related inpatients, appropriate prophylaxis and/or therapy outpatients inpatients.

Language: Английский

---

Molecular Simulation of the Effect of Electron Donor/Acceptor Groups on Fluvoxamine/Serotonin Interactions as a Strategy for COVID‐19 Mitigation

ChemistrySelect, Journal Year: 2023, Volume and Issue: 8(42)

Published: Nov. 8, 2023

Abstract Fluvoxamine has been proven in studies to improve the immune system by reabsorbing serotonin and be beneficial limiting spread of covid‐19 (in early stages disease). The interaction between pristine fluvoxamine drug serotonin, as well NO 2 /NH doped was investigated this work using quantum theory atom molecule (QTAIM) density‐functional (DFT) at B3LYP/6‐311+G (d,p) (gas phase water media) computational level. NH doping on significantly increased adsorption energy improved dipole moment, solvent energy, chemical hardness/softness, charge/energy transfer. On other hand, according results study, compared had no significant effect electronic properties such HOMO/LUMO orbital its gap. From results, binding most stable structure (Complex‐A) measured 12.59 11.65 kcal/mol. Based analysis, an assessment stability studied systems gas reveals following trend: Fluvoxamine‐NH2>Fluvoxamine‐NO2>Fluvoxamine‐NH2/Ser>Fluvoxamine‐NO2/Ser, with corresponding gaps 4.12, 2.65, 1.98, 1.63 eV, respectively. Therefore, is a harmless does not change drug. It seems that increasing absorption functional group can help reduce therapeutic dose make more effective.

Language: Английский

---

COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants—A Scoping Review

Journal of Clinical Psychopharmacology, Journal Year: 2022, Volume and Issue: 42(3), P. 284 - 292

Published: April 14, 2022

Studies for repurposed drugs in severe acute respiratory syndrome coronavirus type 2-infected and disease 2019 (COVID-19) patients are ongoing. According to preclinical research, antidepressants (ADs) might be useful the treatment of COVID-19.

Language: Английский

---

Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(21), P. 13623 - 13623

Published: Nov. 7, 2022

The coronavirus disease 2019 (COVID-19) pandemic continues to cause significant morbidity and mortality worldwide. Since a large portion of the world's population is currently unvaccinated or incompletely vaccinated has limited access approved treatments against COVID-19, there an urgent need continue research on treatment options, especially those at low cost which are immediately available patients, particularly in low- middle-income countries. Prior vitro observational studies have shown that fluoxetine, possibly through its inhibitory effect acid sphingomyelinase/ceramide system, could be promising antiviral anti-inflammatory COVID-19. In this report, we evaluated potential activities fluoxetine K18-hACE2 mouse model SARS-CoV-2 infection, variants concern vitro, i.e., ancestral strain, Alpha B.1.1.7, Gamma P1, Delta B1.617 Omicron BA.5. Fluoxetine, administrated after significantly reduced lung tissue viral titres expression several inflammatory markers (i.e., IL-6, TNFα, CCL2 CXCL10). It also inhibited replication all vitro. A modulation ceramide system tissues, as reflected by increase ratio HexCer 16:0/Cer 16:0 fluoxetine-treated mice, may contribute explain these effects. Our findings demonstrate properties activity concern, establishing very candidate for prevention infection pathogenesis.

Language: Английский

---

Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study

European Neuropsychopharmacology, Journal Year: 2023, Volume and Issue: 71, P. 96 - 108

Published: April 4, 2023

The World Health Organization has proposed that a search be made for alternatives to vaccines the prevention and treatment of COVID-19, with one such alternative being selective serotonin reuptake inhibitors (SSRIs). This study thus sought assess: impact previous SSRI antidepressants on severity COVID-19 (risk hospitalisation, admission an intensive care unit [ICU], mortality), its influence susceptibility SARS-CoV-2 progression severe COVID-19. We conducted population-based multiple case-control in region north-west Spain. Data were sourced from electronic health records. Adjusted odds ratios (aORs) 95%CIs calculated using multilevel logistic regression. collected data total 86,602 subjects: 3060 cases PCR+, 26,757 non-hospitalised PCR+ 56,785 controls (without PCR+). Citalopram displayed statistically significant decrease risk hospitalisation (aOR=0.70; 95% CI 0.49-0.99, p = 0.049) (aOR=0.64; 0.43-0.96, 0.032). Paroxetine was associated mortality (aOR=0.34; 0.12 - 0.94, 0.039). No class effect observed SSRIs overall, nor any other found remaining SSRIs. results this large-scale, real-world indicate that, citalopram, could candidate drug repurposed as preventive aimed at reducing patients' progressing stages disease.

Language: Английский

---

Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study

Molecular Psychiatry, Journal Year: 2023, Volume and Issue: 28(12), P. 5411 - 5418

Published: March 3, 2023

Abstract Prior research suggests that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) used for the treatment of obsessive-compulsive disorder and major depressive disorder, could be repurposed against COVID-19. We undertook prospective interventional open-label cohort study to evaluate efficacy tolerability fluvoxamine among inpatients with laboratory-confirmed COVID-19 in Uganda. The main outcome was all-cause mortality. Secondary outcomes were hospital discharge complete symptom resolution. included 316 patients, whom 94 received addition standard care [median age, 60 years (IQR = 37.0); women, 52.2%]. Fluvoxamine use significantly associated reduced mortality [AHR 0.32; 95% CI 0.19–0.53; p < 0.001, NNT 4.46] increased resolution [AOR 2.56; 1.53–5.51; 4.44]. Sensitivity analyses yielded similar results. These effects did not differ by clinical characteristic, including vaccination status. Among 161 survivors, time 0.81, (0.54–1.23), 0.32]. There trend toward greater side (7.45% versus 3.15%; SMD 0.21; χ 2 3.46, 0.06), most which light or mild severity none serious. One hundred mg prescribed twice daily 10 days well tolerated resolution, without significant increase discharge, Large-scale randomized trials are urgently needed confirm these findings, especially low- middle-income countries, where access vaccines approved treatments is limited.

Language: Английский

---

Association of severe mental illness and septic shock case fatality rate in patients admitted to the intensive care unit: A national population-based cohort study

PLoS Medicine, Journal Year: 2023, Volume and Issue: 20(3), P. e1004202 - e1004202

Published: March 13, 2023

Background Patients with severe mental illness (SMI) (i.e., schizophrenia, bipolar disorder, or major depressive disorder) have been reported to excess mortality rates from infection compared patients without SMI, but whether SMI is associated higher lower case fatality (CFRs) among infected remains unclear. The primary objective was compare the 90-day CFR in septic shock and admitted intensive care unit (ICU), after adjusting for social disadvantage physical health comorbidity. Methods findings We conducted a nationwide, population-based cohort study of all adult ICU France between January 1, 2014, December 31, 2018, using French national hospital database. matched (within hospitals) ratio 1:up 4 (matched-controls) age (5 years range), sex, degree deprivation, year hospitalization. Cox regression models were adjustment smoking, alcohol other substance addiction, overweight obesity, Charlson comorbidity index, presence trauma, surgical intervention, Simplified Acute Physiology Score II score, organ failures, source admission (home, transfer ward), length time admission. outcome CFR. Secondary outcomes 30- 365-day CFRs, clinical profiles patients. A total 187,587 identified, including 3,812 2,258 5,246 disorder. Compared controls, significantly schizophrenia (1,052/3,269 = 32.2% versus 5,000/10,894 45.5%; adjusted hazard (aHR) 0.70, 95% confidence interval (CI) 0.65,0.75, p < 0.001), disorder (632/1,923 32.9% 2,854/6,303 45.3%; aHR CI 0.63,0.76, (1,834/4,432 41.4% 6,798/14,452 47.1%; 0.85, 0.81,0.90, 0.001). Study limitations include inability capture deaths occurring outside hospital, lack data on processes care, problems missing miscoding medico-administrative databases. Conclusions Our suggest that, comorbidity, there are improved without. This finding may be result different immunological exposures psychotropic medications, which should further explored.

Language: Английский

---

COVID-19 mortality among selective serotonin reuptake inhibitor users—results from a nationwide cohort

Clinical Microbiology and Infection, Journal Year: 2023, Volume and Issue: 29(8), P. 1075 - 1082

Published: May 6, 2023

To examine differences in mortality and/or severe acute respiratory syndrome between selective serotonin reuptake inhibitor- (SSRI) users and non-SSRI up to 60 days after a positive SARS-CoV-2 real-time reverse transcription PCR test.Retrospective cohort study including all Danish residents above the age of eighteen with test from 26 February, 2020 5 October, 2021. The follow-up period was days. primary outcome all-cause mortality, secondary syndrome. Exposure interest SSRI use. Differences non-users were examined Cox regression.Altogether, 286,447 individuals identified, 7113 met criteria for had mean 50.4 years, 34% males. Non-SSRI 41.4 50% Similar vaccination frequency observed among two groups. Sertraline most commonly used SSRI, followed by citalopram escitalopram. We found 255 deaths (3.6%) 2872 (1.0%). use significantly associated increased hazard ratio 1.32 (95% confidence interval, 1.16 -1.50; p 0.015), even when adjusting age, sex, status, comorbidities.We higher comparing within test. Even considering possible residual confounding, effect intake seems highly unlikely. Our therefore speaks against hypothesis repurposing drugs COVID-19 treatment.

Language: Английский

---

In silico Evaluation of Bisphosphonates Identifies Leading candidates for SARS-CoV-2 RdRp inhibition

Journal of Molecular Graphics and Modelling, Journal Year: 2025, Volume and Issue: 136, P. 108939 - 108939

Published: Jan. 7, 2025

Language: Английский

---